By Will Feuer Shares of Omeros were cut nearly in half after the company said it is discontinuing its late-stage clinical trial evaluating its narsoplimab…
Markets – MarketWatch
Omeros Shares Cut Nearly in Half as it Discontinues Trial Markets – MarketWatch
